CSIMarket
 
Erba Diagnostics, Inc.  (ERB)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) 27
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 1

Erba Diagnostics, Inc.
Erba Diagnostics, Inc. is a global diagnostics company that specializes in the development, manufacturing, and distribution of in vitro diagnostic devices and reagents. The company offers a comprehensive range of products for clinical chemistry, immunology, hematology, diabetes management, and infectious diseases.

Erba Diagnostics focuses on providing innovative and reliable solutions to healthcare professionals and laboratories worldwide. Their products are designed to deliver accurate and timely results, enabling accurate diagnosis, patient management, and disease monitoring. The company's state-of-the-art manufacturing facilities and commitment to quality ensure that their products meet international standards.

With a presence in over 100 countries, Erba Diagnostics has established a strong global network of customers and partners. Through strategic collaborations and acquisitions, they continue to expand their product portfolio and geographical reach. Their commitment to research and development drives continuous improvement and innovation in their offerings.

Overall, Erba Diagnostics, Inc. is a prominent player in the diagnostics industry, known for delivering advanced diagnostic solutions that contribute to better patient care and outcomes.


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cytek Biosciences Inc

Cytek Biosciences Inc. Surges in Revenue, Defying Market Trends

CTKB, the leading cell analysis solutions company, has reported strong financial results for the fourth quarter and fiscal year 2023. The company showcased impressive growth, with income per share rising by 101.19% year on year to $0.04 per share and revenue increasing by 22.058% to $59.00 million.
This growth is particularly noteworthy considering the downward trend in the Laboratory Analytical Instruments sector. CTKB has defied industry peers, who experienced a decline in top-line revenue during the same period. Additionally, when compared sequentially, CTKB demonstrated positive progress, with income per share improving from $-0.05 per share and revenue increasing by 25.054% from $47.18 million.

Cue Health Inc

Cue Health Inc Faces Challenges Amid Declining Revenue and Inventory Decrease



The Laboratory Analytical Instruments company recently announced its financial results for the fiscal year ending December 31, 2023. The report highlighted a significant decline in revenue and a widening shortfall per share compared to the previous reporting season. Additionally, Cue Health Inc, a related company, also reported a substantial net loss and a decrease in inventories. These financial figures provide insights into the company's performance and potential future challenges.
Financial Results:
The Laboratory Analytical Instruments company's revenue for the period ending December 31, 2023, plunged by a staggering 87.193% to $18.80 million. This decline was accompanied by a significant increase in the shortfall per share, which reached $-0.93 compared to $-0.31 in the previous reporting season. While the sequential revenue growth of 7.559% from $17.48 million offers some optimism, the overall financial results are concerning.

Kewaunee Scientific Corporation

Company Weathered Revenue Contraction with Resilience in Recent Financial Report

The stock market is a dynamic and ever-changing landscape, with companies constantly striving to improve their financial standing and deliver value to their shareholders. In this regard, KEQU, also known as Kewaunee Scientific Corporation, has recently announced some truly astonishing income improvements.
According to their third-quarter financial report for 2024, KEQU reported an impressive income improvement of 240%, reaching an impressive $0.85 per share. This remarkable achievement is even more notable considering the backdrop of a fading revenue, which decreased by -24.321% to $46.03 million. Despite this decline, KEQU has managed to significantly boost its profitability, showcasing the company's strong financial management and strategic decision-making.

Harvard Bioscience Inc

Harvard Bioscience Inc Reports Mixed Results in Fourth Quarter of 20232.

Harvard Bioscience Inc, a leader in the Laboratory Analytical Instruments industry, recently released its financial results for the fourth quarter of 2023. While the company reported a surge in its deficit per share and a slight increase in revenue, it also noted a decline in operating earnings and an increase in net deficit. These results have raised questions about the company's performance and future prospects.
In the fourth quarter of 2023, Harvard Bioscience Inc saw its deficit per share increase to $-0.08 from $-0.04 in the previous year. The company also reported a net deficit of $-1.818 million, up from $-1.666 million in the same period a year ago. Despite a modest revenue growth of 0.946% to $28.70 million, the company experienced a decrease in operating earnings by -72.77% to $3.78 million, resulting in a lower operating margin of 13.17%.

Pacific Biosciences Of California Inc

Pacific Biosciences Of California Inc's Remarkable Revenue Growth Raises Concerns About Operational Efficiency

As a Wall Street journalist, it is important to analyze and dissect the financial performance of companies to provide investors with valuable insights. In the case of Pacific Biosciences Of California Inc, the recent announcement of very solid revenue growth of 113.622% year on year to $58.43 million in the October to December 31, 2023 three months is indeed impressive. However, it is concerning to note that the company reported a net loss of $-0.28 per share during this period.
Despite the strong revenue growth, Pacific Biosciences Of California Inc's behavior is surprising, especially when compared to the rest of the Laboratory Analytical Instruments industry, which experienced a decline in revenue by -4.40%. This raises questions about the company's operational efficiency and profitability.






 

Erba Diagnostics's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com